索宝蛋白
(603231)
| 流通市值：18.16亿 | | | 总市值：32.72亿 |
| 流通股本：1.06亿 | | | 总股本：1.91亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 487,722,648.24 | 1,748,098,617.55 | 1,240,274,258.89 | 773,865,920.48 |
| 营业收入 | 487,722,648.24 | 1,748,098,617.55 | 1,240,274,258.89 | 773,865,920.48 |
| 二、营业总成本 | 452,399,406.08 | 1,539,225,328.77 | 1,075,039,263.85 | 666,429,394.26 |
| 营业成本 | 429,331,235.17 | 1,456,464,077.36 | 1,018,141,139.7 | 628,831,290.74 |
| 税金及附加 | 1,979,285.78 | 9,175,522.41 | 7,011,829.39 | 4,679,314.76 |
| 销售费用 | 4,798,787.58 | 26,063,266.38 | 17,461,119.65 | 11,442,949.61 |
| 管理费用 | 10,725,311.66 | 42,542,350.52 | 31,000,410.69 | 22,168,299.07 |
| 研发费用 | 1,633,326.81 | 8,122,201.16 | 5,469,908.59 | 3,253,258.06 |
| 财务费用 | 3,931,459.08 | -3,142,089.06 | -4,045,144.17 | -3,945,717.98 |
| 其中:利息费用 | 82,131.15 | 80,950.04 | 76,358.07 | 77,609.38 |
| 其中:利息收入 | 1,685,396.28 | 3,398,607.92 | 2,311,455.36 | 1,005,109.95 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,641,045.72 | 5,275,163.24 | 4,014,063.08 | 2,926,444.79 |
| 加:投资收益 | -297,488.78 | 2,838,359.07 | 1,581,978.35 | 702,493.6 |
| 资产处置收益 | 7,812.72 | 30,270.73 | -499,484.8 | -499,658.78 |
| 资产减值损失(新) | - | -2,347,992.39 | 16,626.41 | 16,626.41 |
| 信用减值损失(新) | -50,742.55 | -733,180.72 | -365,080.09 | -242,456.59 |
| 其他收益 | 951,624.37 | 13,105,910.78 | 7,066,622.65 | 6,506,503.89 |
| 四、营业利润 | 37,575,493.64 | 227,041,819.49 | 177,049,720.64 | 116,846,479.54 |
| 加:营业外收入 | 35,612.14 | 415,460.72 | 313,421.09 | 215,708.95 |
| 减:营业外支出 | 48,603.12 | 3,861,561.73 | 2,724,074.79 | 393,506.69 |
| 五、利润总额 | 37,562,502.66 | 223,595,718.48 | 174,639,066.94 | 116,668,681.8 |
| 减:所得税费用 | 6,064,964.39 | 33,879,367.2 | 27,951,169.53 | 19,236,287.73 |
| 六、净利润 | 31,497,538.27 | 189,716,351.28 | 146,687,897.41 | 97,432,394.07 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 31,497,538.27 | 189,716,351.28 | 146,687,897.41 | 97,432,394.07 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 31,781,029.71 | 189,716,351.28 | 146,687,897.41 | 97,432,394.07 |
| 少数股东损益 | -283,491.44 | - | - | - |
| 扣除非经常损益后的净利润 | 29,825,299.25 | 181,419,976.54 | 141,826,384.5 | 93,203,836.86 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.17 | 0.99 | 0.77 | 0.51 |
| (二)稀释每股收益 | 0.17 | 0.99 | 0.77 | 0.51 |
| 八、其他综合收益 | -8,507.93 | 11,335.77 | 21,391.58 | 31,626.37 |
| 归属于母公司股东的其他综合收益 | -8,507.93 | 11,335.77 | 21,391.58 | 31,626.37 |
| 九、综合收益总额 | 31,489,030.34 | 189,727,687.05 | 146,709,288.99 | 97,464,020.44 |
| 归属于母公司股东的综合收益总额 | 31,772,521.78 | 189,727,687.05 | 146,709,288.99 | 97,464,020.44 |
| 归属于少数股东的综合收益总额 | -283,491.44 | - | - | - |
| 公告日期 | 2026-04-30 | 2026-04-24 | 2025-10-31 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |